-
Proceedings of the Royal Society of... 1924
PubMed: 19983505
DOI: No ID Found -
Israel Journal of Medical Sciences Sep 1983
Topics: Adiposis Dolorosa; Diagnosis, Differential; Female; Humans; Joint Diseases; Knee Joint; Middle Aged
PubMed: 6643030
DOI: No ID Found -
Der Hautarzt; Zeitschrift Fur... Oct 2010Lipohyperplasia dolorosa and lymphedema are completely different disease entities, which are both, however, classified under lymphology. While in lipohyperplasia... (Review)
Review
Lipohyperplasia dolorosa and lymphedema are completely different disease entities, which are both, however, classified under lymphology. While in lipohyperplasia dolorosa a congenital lipid distribution disorder leads to a high volume insufficiency and the corresponding clinical symptoms, lymphedema is characterized by a congenital transport incompetence of the vessels or acquired disorders of transport capacity. Both lymphedemas of different genesis are familial volume alterations of the affected regions and the increase in volume is irreversible if not exclusively still in stage I or II. According to current knowledge the solid increase in volume by lymphedema is due to a malfunctioning biomechanism by which the release of additional proteoglycans in the homeostasis system of the fluid in the interstital space plays an important role. Removal of this tissue and the sponge-like substance of proteoglycans is the aim of therapeutic approaches. Manual lymph drainage and compression can evacuate the sponge but not remove it. Lymphological liposculpture is a successful dermatosurgical measure even for secondary lymphedema. Reduction of the necessity of complex hemostasis therapy to 20% of the initial value and an adjustment of the affected extremity on the healthy side, represent a clear improvement in quality of life of patients. The same dermatosurgical method, lymphological liposculpture, has been known for many years to fulfil the successfully proven purpose for the treatment of lipohyperplasia dolorosa by the removal of subcutaneous fatty tissue, present as hyperplasia and not hypertrophy. Tenderness and the necessity for complex hemostasis therapy are no longer present or no longer necessary after lymphological liposculpture for lipohyperplasia dolorosa. This condition is permanent because the congenital fatty masses do not reoccur following surgical removal. Lipohyperplasia dolorosa is therefore curable by lymphological liposculpture. For secondary lymphedema a drastic improvement in quality of life of the patient can be achieved by this method which is demonstrated by the adjustment of symmetry of the extremities and reduction or even avoidance of complex hemostasis therapy.
Topics: Adiposis Dolorosa; Body Fat Distribution; Diagnosis, Differential; Drainage; Extracellular Fluid; Homeostasis; Humans; Lipectomy; Lymphedema; Proteoglycans; Plastic Surgery Procedures
PubMed: 20871969
DOI: 10.1007/s00105-010-1987-7 -
Anales Otorrinolaringologicos... 1996Adiposis dolorosa (Dercum's disease) is a rare fat-tissue malady most frequently presenting in middle-aged women as fatty lumps in the body. Its etiology and...
Adiposis dolorosa (Dercum's disease) is a rare fat-tissue malady most frequently presenting in middle-aged women as fatty lumps in the body. Its etiology and pathogenesis isn't known. Two female patients are reported who had symptomatic adiposis dolorosa (32 and 62-year-old).
Topics: Adiposis Dolorosa; Adult; Amitriptyline; Antidepressive Agents; Female; Humans; Middle Aged
PubMed: 8967567
DOI: No ID Found -
Clinics in Dermatology 2018The cutaneous manifestations of obesity and the associated metabolic syndrome (MetS) may present with a wide variety of cutaneous findings, including acanthosis... (Review)
Review
The cutaneous manifestations of obesity and the associated metabolic syndrome (MetS) may present with a wide variety of cutaneous findings, including acanthosis nigricans, acrochordon, cellulitis, psoriasis, hidradenitis suppurativa, acne, and hirsutism. Being aware of such clinical signs and the underlying systemic disorders may facilitate earlier diagnoses, thereby permitting earlier of therapy initiation and prevention of long-term sequelae. In this process, dermatologists are key figures in the early detection of MetS and its clinical manifestations.
Topics: Acanthosis Nigricans; Adiposis Dolorosa; Cellulite; Dermatitis, Seborrheic; Gout; Hidradenitis Suppurativa; Hirsutism; Humans; Hyperandrogenism; Lichen Planus; Metabolic Syndrome; Obesity; Psoriasis; Skin Diseases; Xanthomatosis
PubMed: 29241757
DOI: 10.1016/j.clindermatol.2017.09.014 -
American Journal of Human Genetics Jun 1963
PubMed: 17948485
DOI: No ID Found -
North Carolina Medical Journal May 1949
Topics: Adiposis Dolorosa; Humans; North Carolina
PubMed: 18144126
DOI: No ID Found -
The American Journal of Pathology May 1926
PubMed: 19969701
DOI: No ID Found -
Journal of the American Academy of... Mar 2023
Topics: Humans; Adiposis Dolorosa; Retrospective Studies; Obesity; Pain
PubMed: 36228943
DOI: 10.1016/j.jaad.2022.09.050 -
International Journal of Clinical... Jun 2013In this case report, we describe a patient with Dercum's disease who was successfully managed with metformin. The administration of metformin reduced pain intensity from...
In this case report, we describe a patient with Dercum's disease who was successfully managed with metformin. The administration of metformin reduced pain intensity from 9/10 to 3/10 and favorably affected the profile of inflammatory cytokines (i.e., TNF a, IL-1β, IL-6, and IL-10), adipokines (i.e., adiponectin, leptin, and resistin), and β-endorphin. Because each variable was affected moderately by the drug, in the range of 20 - 30%, it follows that these effects are additive, i.e., they act independently of each other. However, taking into account advances in the pharmacology of metformin, it seems that other phenomena, such as modulation of synaptic plasticity, activation of microglia, and autophagy of the afferents supplying painful lipomas should be taken into consideration. Nonetheless, metformin deserves further exploration in the biology of pain.
Topics: Adiposis Dolorosa; Cytokines; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Neuralgia; Pain Management; Treatment Outcome
PubMed: 23611575
DOI: 10.5414/CP201878